KPI data tables

BioNTech operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.

BioNTech Cash, Cash Equivalents, and Security Investments (Quarterly) (eur_billions)
PeriodCash and cash equivalentsCurrent security investmentsNon-current security investments
Q3 202610.2014.391.573
Q2 20269.7415.0351.858
Q1 20269.9394.6972.127
Q4 20257.6757.1592.402
Q3 202510.0934.2762.336
Q2 202510.2693.3642.356
Q1 202510.1853.5422.128
Q4 20249.7626.5361.061

Source: BioNTech earnings releases and Form 6-K liquidity footnotes (CIK 0001776985). YE2024: Q4 2024 Exhibit 99.2 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000011/ex99250310_bntxxprxq42024x.htm (€9,761.9 / €6,536.2 / €1,061.1 million). Q1 2025: 5 May 2025 earnings release https://investors.biontech.de/news-releases/news-release-details/biontech-announces-first-quarter-2025-financial-results-and (€10,184.9 / €3,542.0 / €2,127.5 million). Q2 2025: 4 Aug 2025 earnings release https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2025/08/biontech-announces-second-quarter-2025-financial-results-and.html (€10,269.5 / €3,363.8 / €2,356.0 million). Q3 2025: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (€10,092.9 / €4,275.6 / €2,336.4 million). YE2025: 10 Mar 2026 earnings release https://www.sec.gov/Archives/edgar/data/1776985/000177698526000016/a991bntxq4_pr.htm (€7,675.4 / €7,158.5 / €2,401.7 million). Q1 2026: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm (€9,939.4 / €4,696.9 / €2,127.0 million). Q2 2026: 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm (€9,741.0 / €5,035.1 / €1,858.1 million). Q3 2026: 6-K Exhibit 99.1 filed 3 Nov 2026 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (€10,200.8 / €4,390.2 / €1,572.8 million). Chart billions = printed millions / 1,000.

BioNTech COVID-19 Vaccine Revenues (Quarterly) (eur_millions)
PeriodCOVID-19 vaccine revenues (€M)
Q3 2026554.3
Q2 202651.9
Q1 202666.9
Q4 2025855.7
Q3 2025853.3
Q2 2025153.3
Q1 2025133
Q4 20241,122.1
Q3 20241,113.9
Q2 202471.9
Q1 2024124.2

Source: BioNTech Form 6-K and Form 20-F revenue notes (CIK 0001776985). Q2 2024 and H1 2024: 6-K Exhibit 99.1, three and six months ended 30 June 2025, https://www.sec.gov/Archives/edgar/data/1776985/000177698525000051/bnt_2025q2ex99x1quarterlyr.htm (€71.9 million and €196.1 million). Q3 2024 and 9M 2024: 6-K Exhibit 99.1, three and nine months ended 30 Sep 2025, https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (€1,113.9 million and €1,310.0 million). FY2024: Form 20-F year ended 31 Dec 2025 Note 6.1, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm (€2,432.1 million). Q1 2025: 6-K Exhibit 99.1, three months ended 31 Mar 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm (€133.0 million). Q2 2025 and H1 2025 / Q2 2026 and H1 2026: 6-K Exhibit 99.1, three and six months ended 30 June 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm (€153.3 million, €286.3 million, €51.9 million, €118.8 million). Q3 2025 and 9M 2025: same Q3 2025 6-K (€853.3 million and €1,139.6 million). FY2025: 20-F Note 6.1 (€1,995.3 million). Q1 2026: Q1 2026 6-K (€66.9 million). Q3 2026: 6-K Exhibit 99.1 filed 3 Nov 2026, three months ended 30 Sep 2026, https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (€554.3 million; nine months €673.2 million).

BioNTech Revenue by Category (Quarterly) (eur_millions)
PeriodCOVID-19 vaccineOut-licensing (BMS pumitamig)Other revenues
Q3 2026554.368351.9
Q2 202651.9053.7
Q1 202666.9051.2
Q4 2025855.7051.7
Q3 2025853.361352.6
Q2 2025153.30107.5
Q1 2025133049.8
Q4 20241,122.1067.9
Q3 20241,113.90130.9
Q2 202471.9056.8
Q1 2024124.2063.4

Source: BioNTech Form 6-K revenue notes (CIK 0001776985). Q2 2025 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000051/bnt_2025q2ex99x1quarterlyr.htm (Q2 2024/2025 and H1). Q3 2025 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698525000065/bnt_2025q3ex99x1quarterlyr.htm (Q3 and 9M 2024/2025, including out-licensing €613.0 million). Form 20-F year ended 31 Dec 2025 Note 6.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm (FY COVID-19 vaccine, out-licensing, other). Q1 2026 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000031/bntxq12026ex991quarterlyre.htm. Q2 2026 6-K Exhibit 99.1 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000055/bntxq22026ex991quarterlyre.htm. Q3 2026 6-K Exhibit 99.1 filed 3 Nov 2026 https://www.sec.gov/Archives/edgar/data/1776985/000177698526000081/bntxq32026ex991quarterlyre.htm (COVID-19 vaccine 554.3, out-licensing 683.0, other 51.9, total 1,289.2). Q4 2024 and Q4 2025 category amounts equal FY minus 9M from those filings.

BioNTech Revenue by Customer (Annual) (eur_millions)
PeriodPfizerGerman Federal Ministry of HealthBristol Myers SquibbOther customers
FY 20251,602627.561327.4
FY 20242,011.7701038.4
FY 20233,293473.6052.4

Source: BioNTech Form 20-F for the year ended 31 Dec 2025, Note 6.1 Revenues from Contracts with Customers, Revenues by customers table. SEC XBRL https://www.sec.gov/Archives/edgar/data/1776985/000177698526000017/R13.htm and HTML 20-F https://www.sec.gov/Archives/edgar/data/1776985/000177698526000023/bntx-20251231.htm (filed 10 Mar 2026, CIK 0001776985). FY2025: Pfizer €1,602.0 million, German Federal Ministry of Health €627.5 million, Bristol Myers Squibb €613.0 million, other customers €27.4 million. FY2024: €2,011.7 / €701.0 / dash / €38.4 million. FY2023: €3,293.0 / €473.6 / dash / €52.4 million. Dashes charted as 0.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
BioNTech (BNTX) - KPIs | Sterling